MacroGenics Enterprise Value over EBITDA from 2010 to 2024
| MGNX Stock | USD 15.70 0.53 3.27% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter -3.5 K | Current Value -3.4 K | Quarterly Volatility 1.2 K |
Check MacroGenics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MacroGenics main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.1 M, Interest Expense of 1.5 M or Selling General Administrative of 37 M, as well as many exotic indicators such as Price To Sales Ratio of 10.6 K, Dividend Yield of 0.0 or PTB Ratio of 4.1 K. MacroGenics financial statements analysis is a perfect complement when working with MacroGenics Valuation or Volatility modules.
MacroGenics | Enterprise Value over EBITDA |
About MacroGenics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include MacroGenics income statement, its balance sheet, and the statement of cash flows. MacroGenics investors use historical funamental indicators, such as MacroGenics's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although MacroGenics investors may use each financial statement separately, they are all related. The changes in MacroGenics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on MacroGenics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on MacroGenics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in MacroGenics. Please read more on our technical analysis and fundamental analysis pages.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 427 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of MacroGenics Correlation against competitors. For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for MacroGenics Stock analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is MacroGenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. If investors know MacroGenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MacroGenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.949 | Quarterly Revenue Growth (0.85) | Return On Assets (0.36) | Return On Equity (0.06) |
The market value of MacroGenics is measured differently than its book value, which is the value of MacroGenics that is recorded on the company's balance sheet. Investors also form their own opinion of MacroGenics' value that differs from its market value or its book value, called intrinsic value, which is MacroGenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MacroGenics' market value can be influenced by many factors that don't directly affect MacroGenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MacroGenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if MacroGenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MacroGenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.